利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.007 秒)

    URINE BIOMARKERS FOR PREDICTION OF RECOVERY AFTER ACUTE KIDNEY INJURY : PROTEOMICS
    1.
    发明公开
    URINE BIOMARKERS FOR PREDICTION OF RECOVERY AFTER ACUTE KIDNEY INJURY : PROTEOMICS 审中-公开
    URINBIOMARKER复苏后急性肾损伤预测：蛋白质组学

    公开(公告)号：EP2668497A4

    公开(公告)日：2015-09-16

    申请号：EP12739834

    申请日：2012-01-20

    申请人： UNIV PITTSBURGH

    发明人： SINGBARTL KAI ,  KELLUM JOHN A

    IPC分类号： G01N33/50 ,  A61M1/14 ,  G01N33/53 ,  G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/60

    摘要： This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.

    DEVICES, SYSTEMS AND METHODS FOR CELL MODIFICATION
    2.
    发明公开
    DEVICES, SYSTEMS AND METHODS FOR CELL MODIFICATION 审中-公开
    设备，系统和细胞修饰方法

    公开(公告)号：EP2485783A4

    公开(公告)日：2014-01-01

    申请号：EP10822672

    申请日：2010-10-07

    申请人： UNIV PITTSBURGH

    发明人： FEDERSPIEL WILLIAM J ,  KELLUM JOHN ALSTON ,  SINGBARTL KAI

    IPC分类号： A61M1/36 ,  A61K35/14 ,  C12N5/078

    CPC分类号： A61M1/3689 ,  A61K35/15 ,  A61K2035/124 ,  A61M1/3687

    摘要： A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist.